We are live on ! Find out more
AEMD icon

Aethlon Medical

7 hedge funds and large institutions have $45.6K invested in Aethlon Medical in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.06% less ownership

Funds ownership: 0.4%0.34% (-0.06%)

50% less funds holding

Funds holding: 147 (-7)

78% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 9

88% less capital invested

Capital invested by funds: $389K → $45.6K (-$344K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
7
Holders Change
-7
Holders Change %
-50%
% of All Funds
0.08%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
Reduced
2
Closed
9
Calls
Puts
Net Calls
Net Calls Change

AEMD Hedge Fund Activity: Q4 2025 in Review

7 of the 8,238 institutional investors tracked by Wall St. Rank reported a position in Aethlon Medical (AEMD) for Q4 2025, worth a combined $45.6K — down 88% from $389K a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of AEMD and 2 opened new positions — a net loss of 7 holders — while 2 trimmed existing stakes and 0 added.

The largest buyer was Morgan Stanley, opening a new position worth an estimated $9.51K. The largest seller was HRT Financial, exiting entirely with an estimated $97K sold.

  • 7 institutional investors held Aethlon Medical (AEMD) as of Q4 2025, down from 14 in Q3 2025.
  • Funds reported $45.6K of Aethlon Medical stock for Q4 2025, down 88% quarter-over-quarter.
  • 2 funds opened new Aethlon Medical positions in Q4 2025 and 9 closed out, a net change of -7 holders.
  • The largest Aethlon Medical buyer in Q4 2025 was Morgan Stanley, an estimated $9.51K added.
  • The largest Aethlon Medical seller in Q4 2025 was HRT Financial, an estimated $97K sold.

Based on aggregated 13F filings for Q4 2025.